Search results

  1. Photos View all

    Image gallery thumbnail
    Image gallery thumbnail
    Image gallery thumbnail
    Image gallery thumbnail
    Image gallery thumbnail
  2. Apr 12

    , partner to develop /Cas therapeutics:

    2 retweets 4 likes
  3. Apr 11

    So now it's clear that has done all these non-MAb-related (mouse) genetics studies w/ orphan/genome editing drug dev in mind.

    1 retweet 8 likes
  4. Apr 11

    Intellia Therapeutics announce a licensing and collaboration agreement to advance Crispr/Cas gene-editing technology

    1 retweet 2 likes
  6. Apr 11

    The Intellia S-1 also includes juicy details about its pact with as well as

    5 retweets 11 likes
  8. Apr 11

    UPDATED: With a $125M Regeneron deal in hand, CRISPR/Cas9 star Intellia files for an

    12 retweets 6 likes
  11. Apr 11

    Whoa Intellia. Filed S1, and has inked a deal with to work on up to 10 targets.

    4 retweets 10 likes
  12. Apr 11

    /Intellia - I love the first target. Transthyretin amyloidosis.

    View conversation Hide conversation
    1 retweet 6 likes
  13. Apr 11

    $125M in cash for Intellia in this deal. As I said before, Intellia is run by very sharp people

    7 retweets 12 likes
  14. Apr 11

    and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

    8 retweets 8 likes
  15. Apr 11

    that is one of ’s fastest growing companies, according to ?

    1 retweet 4 likes
  18. Apr 8

    in ‘bizzaro jerry’ world from last friday?

    1 retweet 3 likes
  19. Apr 8

    nLod [90-min in] ... also ... etc

    1 retweet 7 likes

No results.

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.